Argobio Studio announced it has launched Enodia Therapeutics and completed a €20.7 million ($25 million) seed financing to advance a small-molecule platform for targeted protein degradation at the point of protein synthesis, enabled by proteomics and machine learning.
The seed round was co-led by Elaia, Pfizer Ventures, and Bpifrance as part of the InnoBio investment strategy. Additional participants included Wallonie Entreprendre, MACSF, Institut Pasteur, InvestSud, Sambrinvest, Mission BioCapital, and Argobio. Argobio said it previously helped create Enodia and provided pre-seed funding, and that Enodia is the third Argobio-founded company to secure seed financing in 2025.
Enodia was created after Argobio identified foundational research from an Institut Pasteur researcher. The company’s platform uses machine learning to selectively modulate the SEC61 translocon—an entry point where secreted and transmembrane proteins are directed into the secretory pathway during synthesis—aiming to intervene upstream of disease while avoiding disruption of essential physiological functions. Enodia said its approach combines a large chemical space of inhibitor families with signal-peptide cell line libraries, machine-learning-driven selectivity, proteomics-based secretome analysis, and structural validation to guide rational drug design and pursue targets that have been difficult to drug.
Enodia said the financing will support advancement of its lead program toward preclinical candidate selection over the next year. The company said its initial pipeline focus is inflammatory and autoimmune diseases, with additional opportunities in oncology and viral infections.
KEY QUOTES:
“Enodia is the third of eight companies created by Argobio to achieve seed financing, underscoring the strength and consistency of our studio model. Our operational venture-building approach is designed to rapidly translate Europe’s leading scientific innovation into globally competitive biotech companies. Enodia is a strong example of this model, based on exceptional foundational research from Institut Pasteur and built by Argobio. We are proud to have brought together a high-quality syndicate of leading international investors to support the company through its next stage of development.”
Daniel Sobral, Chief Financial Officer and Head of Corporate Development, Argobio
“We are grateful for the strong support and confidence of our investor syndicate, and in particular for Argobio’s long-term commitment and company-building approach. Working closely with the Argobio team from the outset enabled us to shape Enodia’s strategy and more rapidly assemble our industrial capabilities while also advancing our highly differentiated small-molecule approach to selectively modulating the SEC61 translocon. With this financing, we are well positioned to progress our lead program to preclinical candidate selection over the coming year, representing an important value inflection point for Enodia.”
Yves Ribeill, Chief Executive Officer, Enodia Therapeutics
